HB

HaiHe Biopharma

China - Shanghai
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Small Molecules

HaiHe Biopharma is a life sciences company focused on Small Molecules.

OncologyInfectious Diseases
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT07337694Exploring the Clinical Value of an AI-Assisted Patient Self-Assessment App for Bowel Preparation: A Multicenter Study
N/A
Simmitecan Hydrochloride for Injection
Advanced Solid Tumor
Phase 1
Clinical Trials (1)
NCT01832298Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Phase 1
reference eldecalcitol soft capsule
Healthy
Phase 1
Clinical Trials (1)
NCT05406050Bioequivalence Study of Eldecalcitol Soft Capsule in Healthy Chinese Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT02870036Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT05507294Single Dose Glumetinib in Healthy Chinese Male Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT03117101Study of the AL3810 in the Treatment of Advanced Solid Tumor
Phase 1
Phase 1
Clinical Trials (1)
NCT04856371Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04746612First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
Phase 1
Gumarontinib Tablets
Advanced Solid Tumor
Phase 1
Clinical Trials (1)
NCT03457532A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT04586335Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Phase 1
Gumarontinib Tablets
Advanced Solid Tumor
Phase 1
Clinical Trials (1)
NCT03466268Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Phase 1
CYH33 for tablet
Advanced Solid Tumors
Phase 1
Clinical Trials (1)
NCT03544905Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Phase 1
Phase 1
Clinical Trials (1)
NCT03260179Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
Phase 1
Phase 1/2
Clinical Trials (1)
NCT04338243Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06975618Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT06909877Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1/2
HH2853 Tablets
FL Lymphoma
Phase 1/2
Clinical Trials (1)
NCT04390737Evaluate the Safety and Clinical Activity of HH2853
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04270591Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT04198818A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Phase 1/2
Phase 2
Clinical Trials (1)
NCT05043922A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Phase 2
1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative
Tuberculosis
Phase 2
Clinical Trials (1)
NCT02329730Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Phase 2
5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm
Tuberculosis
Phase 2
Clinical Trials (1)
NCT02336542Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Phase 2
Phase 2/3
Clinical Trials (1)
NCT04254471This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Phase 2/3
ESAT6-CFP10
Tuberculosis
Phase 3
Clinical Trials (1)
NCT02623556Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
Phase 3
Phase 4
Clinical Trials (1)
NCT02901288Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 25 clinical trials